Alongside our review of our most popular Oncology Central articles of 2015, we’ve also had a look back at which news headlines were of most interest to the readers of Oncology Central last year. From immunotherapy to red meat, catch up on all the these top news stories below.
The results of a Phase III randomized trial presented at the 2015 ASCO meeting indicated that the use of nivolumab alone or in combination with ipilimumab for the treatment of advanced melanoma is more effective than the use of ipilimumab alone.
Notch-inhibiting gamma secretase inhibitors (GSI), a new class of drug that could represent a novel therapeutic approach for breast cancer, were reported to produce promising results in women with estrogen receptor-positive breast cancer.
Mismatch repair deficiency could represent the first genomic marker that can be leveraged to predict patient response to the checkpoint inhibitor pembrolizumab, suggested a new study presented at the 2015 ASCO meeting.
Two studies presented at the recent 2015 San Antonio Breast Cancer Symposium suggest that liquid biopsy could help predict therapy response in women with advanced breast cancer and reveal genetic mutations that can impact prognosis.
Data regarding the safety and efficacy of the PD-1 inhibitor nivolumab in patients with hepatocellular carcinoma were reported at the 2015 ASCO meeting, indicating that 19% of evaluable patients (n = 42) responded to the treatment, displaying tumor reduction in excess of 30%.
A first-in-human study reported at ASH 2015 combined natural killer cells with high-dose chemotherapy and stem cell transplantation for multiple myeloma therapy and reported few of the side effects associated with standard treatments.
Arguably one of the biggest lifestyle and cancer findings to hit the headlines in 2015 was the announcement by WHO stating that there is sufficient evidence to classify processed meats Group 1 carcinogenic, with each 50 g portion consumed daily increasing risk of colorectal cancer by 18%.